Forbes - Revenue rose 10.3 percent from the prior year to an all-time high of 708.47 billion yen, led by a 28.7 percent surge in global sales of its diabetes treatment drug piglitazone, known in Japan as Actos, to 207.7 billion yen. The results were ahead of ...
